ABBV vs VST: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Vistra Corp. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-19.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Vistra Corp. · Utilities
$140.67
-23.0% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
ABBV has more upside to fair value
(-1.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
VST |
| Current Price |
$261.70 |
$140.67 |
| Fair Value Estimate |
$259.04 |
$108.27 |
| Upside to Fair Value |
-1.0%
|
-23.0%
|
| Market Cap |
$462.4B |
$47.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
10.3x
|
| Price / Sales |
7.2x
|
3.0x
|
| Price / FCF |
23.6x
|
34.7x
|
| Revenue Growth YoY |
+10.2%
|
-5.5%
|
| Gross Margin |
71.5%
|
13.0%
|
| Operating Margin |
29.3%
|
2.3%
|
| Return on Equity |
-136.5%
|
41.5%
|
| Dividend Yield |
2.61% |
0.65% |
| FCF Yield |
4.25%
|
2.88%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Vistra Corp. is a vertically integrated independent power producer and retail electricity supplier operating roughly 38,700 megawatts of generation across natural gas, nuclear, coal, solar, and battery storage, serving about 4.3 million retail customers in 20 states and the District of Columbia. The business quality is mixed: the diversified PJM and ERCOT fleet plus retail load is a genuine struc…
Accumulation Zones
| Metric |
ABBV |
VST |
| Zone Low |
$194.28 |
$81.20 |
| Zone High |
$220.18 |
$92.03 |
| In Buy Zone? |
No
|
No
|